2022-2029 年全球周围神经病变市场

市场概览

预计到 2021 年，周围神经病变的市场规模将达到 15.39 亿美元，在预测期间（2022-2029 年）以 4.2% 的复合年增长率增长。

外周神经病变是一种在大脑或脊髓与身体其他部位之间传递信息的神经受损或功能障碍的疾病。周围神经构成了一个不可预知的系统，它将大脑和脊髓与肌肉、皮肤和内臟相连。周围神经从脊髓发出。这些神经受损会干扰大脑与身体其他部位之间的交流，抑制肌肉发育并引起疼痛。

市场动态

周围神经病变市场受到人口增长、糖尿病发病率上升、癌症治疗化疗药物的增加以及对周围神经病变的认识不断提高的推动。

化疗药物的增长和慢性病患病率的上升预计将推动市场增长。

由于糖尿病的流行、用于癌症生长的化疗药物的兴起以及对边缘神经病变的态度不断上升，周围神经病变市场正在增长。例如，根据 2020 年国际糖尿病联盟的数据，全球约有 4.93 亿 20-79 岁的成年人患有糖尿病。预计到 2045 年，这一数字将增加并达到 7 亿。糖尿病患者可能会因糖尿病而出现周围神经病变。对一般人群的调查显示，7% 到 18% 的成年人患有持续性神经病变，详细频率为每年 1000 人。在英国，26% 的糖尿病患者会出现边缘性神经性疼痛。这些因素将在预测期内推动周围神经病变市场的增长。

市场上知名企业扩大兼併、收购和合作，鼓励组织通过创新进入新市场。例如，2019 年 2 月，梯瓦製药工业有限公司推出仿製药 Sabril 片剂进入美国市场。 Teva 拥有超过 550 种常规配方，拥有 FDA 批准的非独家产品的最大放置位置，并在第一位置文件开口方面保持领先地位。这种药片有严重的副作用，包括周围神经病变。

周围神经病变被认为是糖尿病患者进行非最差消融治疗的最持久原因。收集的数据应在未来用于开发治疗周围神经病变的药物和治疗方法。

2019 年 12 月，InvaGen Pharmaceuticals, Inc. 将获得美国食品药品监督管理局 (US FDA) 对 25mg 至 300mg 普瑞巴林胶囊非正式新药申请 (ANDA) 的最终批准。普瑞巴林胶囊适用于治疗与糖尿病周围神经病变相关的神经性疼痛。

预计与药品相关的严格法规将阻碍市场增长。

由于周围神经病变的复杂症状，对治疗剂的副作用和误诊的严格规定预计将阻碍预测期内的市场增长。

行业分析

全球外周神经病变市场根据包括波特五力、监管分析、供应链分析和定价分析在内的各种行业因素对市场进行了深入分析。

细分分析

在全球周围神经病变市场中，糖尿病周围神经病变部分预计将占据最大的市场份额

按类型，周围神经病变市场分为糖尿病周围神经病变、化疗引起的周围神经病变、特发性周围神经病变、HIV/AIDS 相关周围神经病变等。由于糖尿病周围神经病变在年轻糖尿病患者中的患病率不断增加，糖尿病周围神经病变部分占据了最大的市场份额。糖尿病性神经病变是一种神经损伤，如果您患有糖尿病，可能会发生这种损伤。高血糖会损害全身的神经。糖尿病性神经病变经常损害腿部和足部的神经。据说大约 60% 到 70% 的糖尿病患者最终会发展为周围神经病变，但并非所有人都患有疼痛。

化疗引起的周围神经病变领域预计将出现积极的市场增长，因为它通常用于接受化疗的患者。虽然不同类别的化学治疗师可以比较化疗引起的周围神经病变的临床诱导，但每类药物都被提出在不同的系统中引起神经病变，存在着令人生畏的对比。有人指出，神经病变的发生和发展背后有多种因素。大多数从临床前研究中创建的药理学操作员都忽略了减轻副作用。

随着患者体验的增加，HIV/AIDS 相关周围神经病变的副作用通常包括消耗、僵硬、刺痛、震颤，以及脚趾和脚底倾斜死或缺失。手指、手和手腕的神经也会受到影响。一般来说，下肢疼痛可能表明神经病变越来越严重。根据 2021 年周围神经病变基金会，估计约有 33% 的 HIV/AIDS 患者会出现某种形式的周围神经病变。在 HIV/AIDS 患者中，周围神经病变可由感染本身、用于治疗 HIV/AIDS 的某些药物、各种并发症或手部疾病引起。

此外，市场还根据药物疗法、非药物疗法、物理疗法、手术等进行细分。由于一线治疗在周围神经病变治疗中的大量使用，药物治疗部分占据了最高的市场份额。例如，非甾体镇静剂 (NSAID)、抗抑郁药、镇痛药和抗癫痫药被大量专业药理学家单独使用或混合使用以用于指定给药。这些药物提供适度的充分性、可能的症状和依从性。

非药物疗法用于在不使用药物的情况下减轻疼痛。这种治疗应反映当时最成问题的行为症状和患者的理解水平，并根据发育阶段调整治疗。

区域分析

北美在全球周围神经病变市场中占有最大份额

按地区划分，北美主导着周围神经病变市场。由于该地区糖尿病患病率的上升，预计在预测期内将以最高的复合年增长率增长。根据 2020 年皇家药学会的数据，在加拿大，17.9% 的人口报告伴有神经性症状的慢性疼痛，儘管加拿大最近的一项调查报告的比例较低。美国的一项研究发现，通过临床检查或自我报告确定的周围神经病变的患□□病率分别为 9.8% 和 12.4%。该地区目睹了患有各种神经系统疾病的人的发病率上升，刺激了市场的增长。预计在预测期内，增加周围神经病变治疗的研发支出也将提振市场需求。

由于患有糖尿病和癌症等慢性病的老年人越来越多，预计亚太地区将占据很大的市场份额。该地区的医疗保健部门正在发展，这正在推动市场发展。中国和印度等国家人口众多，中产阶级收入水平的提高为医疗保健支出创造了更多空间。这些因素在预测期内刺激了市场增长。

竞争格局

由于存在多个国际和国内市场，周围神经病变市场是一个竞争激烈的市场。产品多样化、收入安全和机会使市场更具竞争力。葛兰素史克、雅培、Cipla 实验室、诺华公司、默克公司、百时美施贵宝、Lady's Lab、辉瑞、礼来公司。礼来公司拥有重要的市场份额，已成为主要的市场参与者主要参与者正在利用产品开发、新产品发布、市场扩张和产品多元化战略来维持其市场地位。

公司参与研究合作、合併、战略合作伙伴关係、收购和新产品发布，以增加全球对周围神经病变治疗的需求。例如：

• 2020 年 7 月，美国食品药品监督管理局 (FDA) 批准了一种局部、非全身、非阿片类药物疼痛治疗，以贴片的形式提供，用于治疗与足部周围神经病变相关的神经性疼痛。已批准该药物，昆坦萨。
• 2020年7月，百时美施贵宝与蓝鸟生物宣布联合开发B细胞发育抗原（BCMA）协同致幻抗原受体（CAR）T细胞免疫疗法，美国食品药品监督管理局（FDA） ) for idecabtagene vicleucel. 宣布向 (FDA) 提交生物製品许可申请 (BLA)，用于治疗患有背部和无法控制的大量骨髓瘤的成年患者。

值得关注的重点公司

Averitas 製药

概述。它是 Grunenthal Group 的美国商业子公司，Grunenthal Group 是一家从事治疗炎症、疼痛和痛风药物研发的跨国製药公司。其产品和服务部署在 30 多个国家。成立于2018年，总部位于德国。

按产品类型划分的投资组合。

QUTENZA（辣椒素）：一种非全身性、非阿片类药物，用于成人治疗与带状疱疹后神经痛和糖尿病足部周围神经病相关的神经性疼痛。

重大进展。 2021 年 3 月，Averitas Pharma 宣布进行一项 3 期研究，以观察 QUTENZA 在术后神经性疼痛中的疗效和安全性。

全球外周神经病变市场报告包括大约 45 多个市场数据表、40 多个数字和 180 页。

内容

第1章研究方法与范围

• 调查方法
• 调查目的和范围

第 2 章市场定义和概述

第 3 章执行摘要

第 4 章市场动态

• 市场影响因素
  • 驱动程序
    • 慢性病患病率上升
    • 增加化疗药物
  • 限制因素
    • 严格的规定
  • 商机
  • 影响分析

第5章行业分析

• 波特五力分析
• 监管分析
• 供应链分析
• 定价分析

第 6 章按类型

• 糖尿病周围神经病变
• 化疗引起的周围神经病变
• 特发性周围神经病
• 其他

第 7 章治疗

• 药物治疗
  • 止痛药
  • 抗惊厥药
  • 抗抑郁药
• 非药物治疗
  • 经皮神经电刺激疗法
  • 血浆置换/静脉注射免疫球蛋白治疗
  • 其他

第 8 章最终用户

• 医院
• 诊所
• 门诊
• 其他

第 9 章按地区

• 北美
  • 美国
  • 加拿大
  • 墨西哥
• 欧洲
  • 德国
  • 英国
  • 法国
  • 其他欧洲地区
• 南美洲
  • 巴西
  • 阿根廷
  • 其他南美洲
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 澳大利亚
  • 其他亚太地区
• 中东和非洲

第 10 章竞争格局

• 竞争场景
• 市场定位/市场份额分析
• 併购分析

第 11 章公司简介

• Averitas Pharma
  • 公司简介
  • 表格组合和说明
  • 主要亮点
  • 财务摘要
• Cipla Laboratories
• Merck and Co
• Bristol Meyer Squibb
• Reddy's Lab
• Elli Lilly and Company
• Teva Pharmaceutical Industries
• GlaxoSmithKline
• Novartis AG
• Abbott Laboratories

第12章 全球周围神经病变市场-DataM

Market Overview

Peripheral Neuropathy Market size was valued US$ 1,539 million in 2021 and is estimated to reach US$ XX million by 2029, growing at a CAGR of 4.2% during the forecast period (2022-2029).

Peripheral neuropathy is a disorder when nerves that convey messages to and from the mind and spinal line from the remainder of the body are harmed or ailing. The peripheral nerves make up an unpredictable system that interfaces the brain and spinal string to the muscles, skin, and inside organs. Peripheral nerves come out of the spinal line. They are masterminded along lines in the body called dermatomes when damage to a nerve influence at least one dermatomes, which can be followed to specific regions of the body, harm to these nerves interferes with correspondence between the cerebrum and different pieces of the body and can disable muscle development and cause torment.

Market Dynamics

The peripheral neuropathy market is driven by the rising population, growing commonness of diabetes, increasing chemotherapy medicines for cancer growth, and rising mindfulness about fringe neuropathy.

Increasing chemotherapy medicines and rising prevalence of chronic diseases are expected to drive market growth.

The peripheral neuropathy market is expanding due to growing commonness of diabetes, increasing chemotherapy medicines for cancer growth, and rising mindfulness about fringe neuropathy. For instance, according to the International Diabetes Federation 2020, approximately 493 million adults of age-groups 20-79 have diabetes worldwide. This number is expected to increase and reach up to 700 million by 2045. Individuals with diabetes are probably going to experience the ill effects of diabetes-instigated fringe neuropathy. General population studies have revealed that 7% to 18% of adults now have incessant neuropathic torment, where the detailed frequency is 1000 individuals for every year. Alone, in the UK the 26% of people with diabetes experience fringe neuropathic torment. These factors will drive the growth of the peripheral neuropathy market in the forecast period.

Expanding mergers, acquisitions, and coordinated efforts by conspicuous players in the market encourage organizations to enter the new market with inventive innovations. For instance, in February 2019, Teva Pharmaceutical Industries Ltd launched a generic version of Sabril tablets to enter the US market. With more than 550 conventional prescriptions accessible, Teva has the biggest arrangement of FDA-endorsed nonexclusive items and holds the main situation in first-to-document openings. The tablets have serious side effects include peripheral neuropathy.

Peripheral neuropathy is perceived as the most continuous reason for non-awful removal in diabetic patients. The Neuropathy Association makes attention to peripheral neuropathy by furnishing patients with the essential assets, data, and apparatuses to manage to discover medicines. The collected data should be used to develop pharmaceuticals and the treatment of peripheral neuropathy in the future.

In December 2019, InvaGen Pharmaceuticals, Inc., get final approval for its Abbreviated New Drug Application (ANDA) for Pregabalin Capsules of 25mg to 300mg from the United States Food and Drug Administration (US FDA). Pregabalin capsules are indicated for the cure of neuropathic pain associated with diabetic peripheral neuropathy.

Stringent regulations associated with the medications are expected to hamper the market growth.

The stringent regulations regarding the side effects of the medicines use in the treatment, and the misdiagnosis of peripheral neuropathy due to its complex array of symptoms will hinder the market growth in the forecast period.

Industry Analysis

The global peripheral neuropathy market provides in-depth analysis of the market based on various industry factors such as porter's five forces, regulatory analysis, supply chain analysis and pricing analysis.

Segment Analysis

Diabetic peripheral neuropathy segment is expected to hold the largest market share in global peripheral neuropathy market

The peripheral neuropathy market is segmented by type into diabetic peripheral neuropathy, chemotherapy-induced peripheral neuropathy, idiopathic peripheral neuropathy, HIV/AIDS associated peripheral neuropathy and others. The diabetic peripheral neuropathy segment held the largest market share due to the increasing prevalence of diabetic peripheral neuropathy in youth suffering from diabetes. Diabetic neuropathy is a kind of nerve harm that can happen if you have diabetes. High blood sugar will harm nerves all through the body. Diabetic neuropathy regularly harms nerves in the legs and feet. About 60% to 70% of all people with diabetes will eventually develop peripheral neuropathy, although not all suffer pain.

The Chemotherapy-induced peripheral neuropathy segment is expected to have positive market growth due to its use common in patients receiving anticancer treatment. Although chemotherapy-induced peripheral neuropathy's clinical introduction can be comparable with the different classes of chemotherapeutic specialists, there are unpretentious contrasts, proposing that each class of medications may incite neuropathy using various systems. Different components have been proposed to underlie the turn of events and support of neuropathy. Most pharmacological operators created from preclinical trials have neglected to reduce the side effects.

HIV/AIDS associated peripheral neuropathy side effects on patients as a rule experience incorporate consuming, firmness, prickling, shivering, and deadness or lost inclination in the toes and bottoms of the feet. The nerves in the fingers, hands, and wrists are additionally influenced. Generally extraordinary, torment over the lower legs could show increasingly serious nerve harm. According to the Foundation for Peripheral Neuropathy 2021, it is estimated that about 33% of individuals with HIV/AIDS experience some fringe nerve harm. For patients with HIV/AIDS, peripheral neuropathy can be brought about by the infection itself, by specific medications utilized in the treatment of HIV/AIDS or different intricacies, or because of deft diseases.

Further, the market is also classified based on pharmacological therapies, non-pharmacological therapies, physical therapies, surgery, and others. The pharmacological therapies segment accounts for the highest market share due to the high usage of primary in peripheral neuropathy treatment. A huge array of pharmacologic specialists, for example, nonsteroidal calming drugs (NSAIDs), antidepressants, analgesics, and antiepileptic drugs, are utilized alone or in the blend for indicative administration. These medications bring about moderate adequacy, possible symptoms, and medication cooperation.

Non-Pharmacological therapies are used to decrease pain without the use of medicine. In this therapy, the treatments should be modified for the developmental stages, reflecting both the most problematic behavioral symptoms at that stage in time and the patient's level of understanding.

Geographical Analysis

North America region holds the largest market share in the global peripheral neuropathy market

By region, North America is dominating the peripheral neuropathy market. It is expected to grow at the highest CAGR over the forecast period due to the increasing prevalence of diabetes in the region. According to the Royal Pharmaceutical Society 2020, in Canada, 17.9% of the population reported chronic pain with neuropathic symptoms; however, a recent Canadian study has reported lower percentages. A study in the United States revealed that the prevalence rates for peripheral neuropathy determined by either clinical examination or self-reporting were 9.8% and 12.4%, respectively. The rising incidences of people suffering from various neuropathy problems in the region have fueled the market's growth. The higher spending on the research and development activities for treating peripheral neuropathy shall boost the market demand over the forecast period.

The Asia-Pacific region is expected to have a large market share due to the increasing number of geriatric populations afflicted with chronic diseases like diabetes and cancer. The developing healthcare sector in the region has boosted the market. Countries like China and India have a huge population; also, the rise in the middle class's income level has given them the capacity to spend on health care. These factors stimulate market growth over the forecasted period.

Competitive Landscape

The peripheral neuropathy market is highly competitive with the presence of several international and local markets. Product diversification, revenue generation, and opportunities intensify the market competition. GlaxoSmithKline, Abbott Laboratories, Cipla Laboratories, Novartis AG, Merck and Co., Bristol Meyer Squibb, Reddy's Lab, Pfizer and Elli Lilly and Company, Eli Lilly are the leading market players with significant market share. The major players are using product development, novel product launches, market expansion, and product diversification strategies for holding their position in the market.

The companies enter into collaborations, mergers, strategic partnerships, acquisitions and novel product launches to increase the demand for peripheral neuropathy treatment across the globe. For instance,

• In July 2020, The Food and Drug Administration (FDA) had approved Qutenza, a topical, non-systemic, non-opioid pain treatment delivered in the form of a patch for neuropathic treatment pain with peripheral neuropathy of the feet.
• In July 2020, Bristol Myers Squibb and bluebird bio reported the accommodation of their Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for idecabtagene vicleucel, the organizations' investigational B-cell development antigen (BCMA)- coordinated illusory antigen receptor (CAR) T cell immunotherapy, for the treatment of grown-up patients with backslid and unmanageable numerous myeloma.

Key Companies to Watch

Averitas Pharma:

Overview: It is an US commercial subsidiary of Grunenthal group, a multinational pharma company that works in research and development of therapeutics for inflammation, pain and gout. Its products and services are present in over 30 countries. It was founded in 2018 and is headquartered in Germany.

Product Type Portfolio:

QUTENZA (Capsaicin): It is a non-systemic and non-opioid that is used in adults for neuropathic pain treatment that is linked with postherpetic neuralgia and diabetic peripheral neuropathy of feet.

Key Developments: In Mar 2021, Averitas pharma announced about conducting phase III trial of QUTENZA to observe its efficacy and safety in post-surgical neuropathic pain.

The global peripheral neuropathy market report would provide an access to an approx. 45+market data table, 40+figures and 180pages.

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

• 4.1. Market Impacting Factors
  • 4.1.1. Drivers:
    • 4.1.1.1. Rising Incidence of Chronic Diseases
    • 4.1.1.2. Increasing chemotherapy medicines
  • 4.1.2. Restraints:
    • 4.1.2.1. Stringent regulations
  • 4.1.3. Opportunity
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1 Porter's Five Forces Analysis
• 5.2 Regulatory Analysis
• 5.3 Supply Chain Analysis
• 5.4 Pricing Analysis

6. By Type

• 6.1. Introduction
  • 6.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
  • 6.1.2. Market Attractiveness Index, By Type
• 6.2. Diabetic Peripheral Neuropathy
  • 6.2.1. Introduction
  • 6.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
• 6.3. Chemotherapy-induced Peripheral Neuropathy
• 6.4. Idiopathic Peripheral Neuropathy
• 6.5. Others

7. By Treatment

• 7.1. Introduction
  • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
  • 7.1.2. Market Attractiveness Index, By Treatment
• 7.2. Pharmacological Therapies
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.2.3. Pain Relievers
  • 7.2.4. Anti-seizure Medications
  • 7.2.5. Antidepressants
• 7.3. Non-pharmacological Therapies
  • 7.3.1. Transcutaneous Electrical Nerve Stimulation
  • 7.3.2. Plasma Exchange and Intravenous Immune Globulin
  • 7.3.3. Others

8. By End-User

• 8.1. Introduction
  • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User.
  • 8.1.2. Market Attractiveness Index, By End User
• 8.2. Hospitals
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis, USD Mn, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
• 8.3. Clinics
• 8.4. Ambulatory Centers
• 8.5. Others

9. By Region

• 9.1. Introduction
  • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
  • 9.1.2. Market Attractiveness Index, By Region
• 9.2. North America
  • 9.2.1. Introduction
  • 9.2.2. Key Region-Specific Dynamics
  • 9.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
  • 9.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
  • 9.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User.
  • 9.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 9.2.6.1. The U.S.
    • 9.2.6.2. Canada
    • 9.2.6.3. Mexico
• 9.3. Europe
  • 9.3.1. Introduction
  • 9.3.2. Key Region-Specific Dynamics
  • 9.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
  • 9.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
  • 9.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User.
  • 9.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 9.3.6.1. Germany
    • 9.3.6.2. The U.K.
    • 9.3.6.3. France
    • 9.3.6.4. Rest of Europe
• 9.4. South America
  • 9.4.1. Introduction
  • 9.4.2. Key Region-Specific Dynamics
  • 9.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
  • 9.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
  • 9.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User.
  • 9.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 9.4.6.1. Brazil
    • 9.4.6.2. Argentina
    • 9.4.6.3. Rest of South America
• 9.5. Asia Pacific
  • 9.5.1. Introduction
  • 9.5.2. Key Region-Specific Dynamics
  • 9.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
  • 9.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
  • 9.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User.
  • 9.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 9.5.6.1. China
    • 9.5.6.2. India
    • 9.5.6.3. Japan
    • 9.5.6.4. Australia
    • 9.5.6.5. Rest of Asia Pacific
• 9.6. The Middle East and Africa
  • 9.6.1. Introduction
  • 9.6.2. Key Region-Specific Dynamics
  • 9.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
  • 9.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
  • 9.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User.

10. Competitive Landscape

• 10.1. Competitive Scenario
• 10.2. Market Positioning/Share Analysis
• 10.3. Mergers and Acquisitions Analysis

11. Company Profiles

• 11.1. Averitas Pharma
  • 11.1.1. Company Overview
  • 11.1.2. Form Portfolio and Description
  • 11.1.3. Key Highlights
  • 11.1.4. Financial Overview
• 11.2. Cipla Laboratories
• 11.3. Merck and Co
• 11.4. Bristol Meyer Squibb
• 11.5. Reddy's Lab
• 11.6. Elli Lilly and Company
• 11.7. Teva Pharmaceutical Industries
• 11.8. GlaxoSmithKline
• 11.9. Novartis AG
• 11.10. Abbott Laboratories

LIST NOT EXHAUSTIVE

12. Global Peripheral Neuropathy Market - DataM

• 12.1. Appendix
• 12.2. About Us and Method of Fixation
• 12.3. Contact Us